ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s share price traded down 5.3% during mid-day trading on Friday . The stock traded as low as $24.25 and last traded at $24.26. 931,743 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 1,332,449 shares. The stock had previously closed at $25.63.
Several equities analysts have issued reports on the company. BidaskClub downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, May 3rd. Raymond James lifted their price objective on ACADIA Pharmaceuticals from $40.00 to $43.00 and gave the company a “strong-buy” rating in a research report on Friday, May 31st. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 6th. Finally, ValuEngine downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 7th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $31.25.
The company has a market cap of $3.66 billion, a P/E ratio of -12.51 and a beta of 2.95. The company has a quick ratio of 6.29, a current ratio of 6.35 and a debt-to-equity ratio of 0.02.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.05). The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.93 million. ACADIA Pharmaceuticals had a negative net margin of 116.10% and a negative return on equity of 79.74%. The firm’s quarterly revenue was up 28.6% on a year-over-year basis. During the same period last year, the business posted ($0.44) earnings per share. On average, equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post -1.9 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Clearbridge Investments LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at $27,000. Metropolitan Life Insurance Co NY grew its stake in shares of ACADIA Pharmaceuticals by 11.0% during the first quarter. Metropolitan Life Insurance Co NY now owns 35,921 shares of the biopharmaceutical company’s stock worth $964,000 after purchasing an additional 3,564 shares during the period. BlueMountain Capital Management LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth $4,519,000. Perceptive Advisors LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth $400,000. Finally, HighTower Advisors LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth $776,000. 93.35% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 5.3%” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2019/06/14/acadia-pharmaceuticals-nasdaqacad-shares-down-5-3.html.
ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Featured Article: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.